Navigation Links
New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

The future of cancer treatment - targeted radiotherapy, on a cellular scale. Antibodies coupled to radioactive isotopes specifically seek out, bind to and kill cancerous cells. Provided that you can find something different on the cell surface between normal and cancerous cells; this is not as easy as it sounds.

A new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy with fewer side effects caused tumors to shrink in 95 percent of patients, a new study by researchers at the University of Michigan Comprehensive Cancer Center found.

Patients with advanced-stage follicular lymphoma ?a cancer generally considered incurable ?who had not been previously treated with any other form of therapy received a single course of treatment with the Bexxar therapeutic regimen, a radioactive antibody injected into the bloodstream that targets and kills cancer cells. Of the 76 patients enrolled in the study, 95 percent responded to the treatment and 75 percent had a complete response, meaning no evidence of cancer remained. More than three-quarters of patients with a complete remission were disease-free after five years.

Results of the study appear in the Feb. 3 New England Journal of Medicine.

"The results of this treatment, which essentially takes only one week to complete, rival any kind of treatment that's been used for follicular lymphoma, including chemotherapy regimens that take months to complete. It's very well-tolerated by patients and we saw complete remission in the majority of patients lasting for years," says lead study author Mark Kaminski, M.D., director of the Leukemia/Lymphoma Program and the Multidisciplinary Lymphoma Clinic at the U-M Comprehensive Cancer Center.

Kaminski and his colleague Richard Wahl (formerly at U-M and now at Johns Hopkins University) developed the Bexxar regimen, which received approval from the U.S. Food and Drug Administration in June 2003 to treat foll
'"/>

Source:University Of Michigan Health System


Page: 1 2 3

Related biology news :

1. Discovery Could Lead To Novel Approaches In HIV Treatment
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Effective Cancer Treatments Follow The Clock
4. Protein Discovery Could Unlock The Secret To Better TB Treatment
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
8. Drug Offers Alternative to Surgical Treatment After Miscarriage
9. Treatments have same target, different responses for lung cancer patients with genetic mutation
10. Minimally Invasive Cancer Treatments Highlighted
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Rivals Chemotherapy For Lymphoma Study Finds

(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... recent study to be published on April 27, 2011, in ... Hazen and colleagues found that oceanographic and prey measurements can ... team from Duke University, Woods Hole, and the Naval Undersea ... features and distributions of prey off the east coast of ...
... add new functions to stainless steel and make it ... by an interdisciplinary team at the University of Alberta ... was developed to address some of the problems associated ... body. Implanted biomedical devices, such as cardiac stents, ...
... CORVALLIS, Ore. - They can be both a blessing and a ... species are found from mountain tops to smoking volcanic vents on the ... to support much of the plant and animal life on Earth. ... And to a large extent, no one cared. Such has been the ...
Cached Biology News:Identifying beaked whale foraging habitat in the tongue of the ocean, Bahamas 2Sweet chemistry: Carbohydrate adhesion gives stainless steel implants beneficial new functions 2Research outlines mysterious evolution of nematodes -- one of Earth’s first animals 2Research outlines mysterious evolution of nematodes -- one of Earth’s first animals 3
(Date:2/26/2015)... , Feb. 26, 2015  Dyadic International, ... whose patented and proprietary technologies are used to ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... its financial results for year ending December 31, ... 2015 and will host a conference call that ...
(Date:2/26/2015)... , Feb. 26, 2015   Lexicon Pharmaceuticals, Inc. ... will present at the Cowen 35 th Annual Health ... EST in Boston .  Lexicon management will ... A webcast of the presentation will be available ... of the presentation will be available at www.lexpharma.com ...
(Date:2/26/2015)... Phosphate Therapeutics, today announces ... pivotal trial of PT20 in subjects with hyperphosphataemia ... has completed as the pre-specified number of randomisations ... leading UK-based scientists from the Medical Research Council ... novel phosphate binder that is based on proprietary ...
(Date:2/25/2015)... Market Publishers Ltd is happy to ... 9Dimen Research have been recently uploaded to its catalogue. ... Research Report . This research report provides wealth of ... world adhesive mortar industry as well as includes an ... regional markets. It focuses on the main regions such ...
Breaking Biology Technology:Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 4
... HILL, N.C., Nov. 5 As biopharmaceutical,companies ... considerable efforts,are placed on strategy and execution ... focus on revenue growth and little else. ... excellence, a recent study,was conducted by Best ...
... - Phase II PC-DAC(TM):Exendin-4 Data in December - ... MONTREAL, Nov. 5 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies,Inc. (TSX:CJB) ... Phase II,clinical trial of PC-DAC(TM):Exendin-4. This Phase II ... that,evaluated the efficacy and safety of three months ...
... BioMarin,Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a company,update at the Credit Suisse 2008 Annual Healthcare ... 10:30 a.m. MST., Interested parties may access a ... section of the BioMarin website, http://www.BMRN.com .,A replay ...
Cached Biology Technology:New Study Provides Key Findings for Biopharma Product Launch Evaluation 2ConjuChem Provides Development Update 2ConjuChem Provides Development Update 3BioMarin to Present at the Credit Suisse Healthcare Conference 2
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
...
Biology Products: